IP Group

News

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.